Robinson, Giles W <br/><br/>
Risk-adapted therapy for young children with medulloblastoma (SJYC07): therapeutic and molecular outcomes from a multicentre, phase 2 trial.  [electronic resource] 

 -  The Lancet. Oncology  06 2018 
 - 768-784 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Comparative Study; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1474-5488 
<br/><br/><label>Standard No.: </label>10.1016/S1470-2045(18)30204-3  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Age Factors<br/>Antineoplastic Combined Chemotherapy Protocols--adverse effects<br/>Australia<br/>Biomarkers, Tumor--genetics<br/>Cerebellar Neoplasms--genetics<br/>Chemotherapy, Adjuvant<br/>Child, Preschool<br/>Clinical Decision-Making<br/>Cranial Irradiation--adverse effects<br/>DNA Methylation<br/>Gene Expression Profiling<br/>Humans<br/>Infant<br/>Medulloblastoma--genetics<br/>Neoadjuvant Therapy--adverse effects<br/>Patient Selection<br/>Predictive Value of Tests<br/>Progression-Free Survival<br/>Radiation Dosage<br/>Radiotherapy, Adjuvant<br/>Risk Assessment<br/>Risk Factors<br/>Time Factors<br/>United States